PATIENT WALLET CARD

Have This Card With You At All Times
Show It To Any Doctor That Sees You And When You Go To The Hospital

You should plan to stay within 2 hours of the location where you received your treatment for at least 4 weeks after getting Kymriah. Your healthcare provider will check to see if your treatment is working and help you with any side effects that occur.
INFORMATION FOR THE HEALTHCARE PROVIDER

This patient has received Kymriah (CAR-T cell) therapy

Following Kymriah treatment, Cytokine Release Syndrome (CRS) can happen. It may include neurological toxicities.

⚠️ Please contact his/her treating oncologist in the following situations:
• before giving steroids or cytotoxic medications
• if the patient has a serious infection
• before the patient undergoes an invasive procedure

Date received Kymriah: ____________________________
Oncologist Name (for Kymriah therapy): __________________
Phone Number: ____________________________

Kymriah is a CD19-directed genetically modified autologous T Cell immunotherapy indicated for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse and adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.

Limitation of Use: KYMRIAH is not indicated for treatment of patients with primary central nervous system lymphoma

KYMRIAH® (lisaleucel-vec) Inspiration for Breakthrough.